The Group That Lost Least Did Best

In young women with endometrial cancer who want to preserve fertility, losing weight is part of the cancer treatment rather than a side project. A study compared three routes — surgery, semaglutide, and an intensive lifestyle program — and found the group that lost the least weight had the highest rate of complete tumor remission.^[1] That is almost certainly not what it looks like, and why it is not is worth understanding.

Why weight matters in this cancer

Endometrial cancer is strongly linked to excess weight, through estrogen produced in fat tissue. In younger women who want to keep the option of pregnancy, standard surgery removes that option — so fertility-sparing treatment uses hormonal therapy and aims to reverse the conditions that produced the cancer. Weight loss is part of the oncological plan.

Ranked by weight lost, surgery came first. Ranked by tumor remission, it came last.

Start with the denominators

That alone accounts for a large share of the apparent ordering. Before reaching for any explanation of why surgery underperformed, the first question is whether the difference exists at all, and 53 people split three ways cannot answer it.

Then the way people ended up in each group

Participants were not randomized. They arrived at their treatment after multidisciplinary assessment and shared decision-making — which is exactly right as clinical practice and fatal to the comparison.

So the most economical explanation for the inverse ordering is not that losing weight surgically harms tumor response. It is that the sickest patients were sent for the most aggressive intervention, and their tumors behaved accordingly.

This is the same problem we have documented repeatedly in observational comparisons of these drugs — treatment assignment carrying information about the patient. The general case is in when a hazard ratio is too good, and what a study can do to earn trust despite it is in how to trust an observational study. This study does none of those things, and does not claim to.

What is worth taking from it anyway

One row survives the criticism better than the others, because it is about the same people over time rather than a comparison between groups: weight regain by two years was 14.3% in the lifestyle group against 55.6% and 66.7%.

That fits everything else this register has documented about maintenance. The drug and the operation produce faster loss; keeping it requires something continuing. Two-thirds of the surgical group regaining within two years is consistent with the wider evidence on weight regain after bariatric surgery, and the semaglutide figure is consistent with what happens when treatment ends.